8-K

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 5, 2010 (August 3, 2010)

GENSPERA, INC.

(Exact name of registrant as specified in Charter)

Delaware	0001421204	20-0438951
(State or other jurisdiction of incorporation or organization)	(Commission File No.)	(IRS Employee Identification No.)

2511 N Loop 1604 W, Suite 204

San Antonio, TX 78258

 (Address of Principal Executive Offices)

210-479-8112

 (Issuer Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01  Regulation FD Disclosure.

On August 3, 2010, GenSpera, Inc. (the “Company”) announced that it had acquired a patent application from John Hopkins University and the University of Copenhagen for technology relating to medical imaging.  A copy of the press release is attached to this report as Exhibit 99.01.

The information contained in this Current Report on Form 8-K and the exhibits attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information or such exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in or exhibits to this Form 8-K shall not be deemed an admission as to the materiality of any information in this report that is required to be disclosed solely to satisfy the requirements of Regulation FD.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 5, 2010

GenSpera, Inc.
By:	/s/ Craig Dionne
	Craig Dionne
	Chief Executive Officer

INDEX OF EXHIBITS

			Incorporated by Reference
Exhibit No.	Description	Filed Herewith	Form	Exhibit No.	File No.	Filing Date
99.01	Press Release dated August 3, 2010	*

EX-99.01

CONTACT:

Company: Craig Dionne, Ph.D., CEO GenSpera, Inc.  (210) 479-8112

Investors: Steve Chizzik The Verrazano Group (908) 688-9111

Media: Deanne Eagle Planet Communications (917) 837-5866

GENSPERA ACQUIRES RIGHTS TO CANCER IMAGING TECHNOLOGY

To Create A New Generation Of Medical Imaging Tools For Oncologists

SAN ANTONIO, Texas, August 3, 2010 – GenSpera, Inc. (OTC.BB: GNSZ) announced that it has  acquired a patent application from the Johns Hopkins University and the University of Copenhagen for technology relating to medical imaging. The technology incorporates derivatives of thapsigargin, the active ingredient in GenSpera’s therapeutics program, coupled with its patented tumor-targeted peptides, to create cancer-specific imaging compounds. When used in conjunction with standard imaging modalities, such as positron emission tomography (PET) or single photon emission computed tomography (SPECT), this technology allows for the detection and monitoring of tumors that have accumulated the imaging compound.

“The acquisition of this intellectual property allows GenSpera to extend its current expertise in thapsigargin chemistry to medical imaging modalities and complements our existing business,” said Dr. Craig Dionne, Chairman and CEO of GenSpera.  “The GenSpera cancer imaging platform has the potential to dramatically improve the ability of oncologists to assess the extent of disease and monitor the ongoing progress of cancer treatments.”

“These thapsigargin derivatives are a natural extension of our work with G-202 and G-115, the lead cancer drugs in GenSpera’s pipeline,” said Dr. Soren Brogger Christensen, Professor of Pharmacognosy at the University of Copenhagen and co-inventor of the technology. “I am delighted that GenSpera has acquired this application as they have the vision, know-how and determination to bring these important potential medical applications to realization.”

About GenSpera:

GenSpera, Inc. is a development stage oncology company focused on therapeutics that deliver a potent, unique and patented drug directly to tumors. GenSpera’s technology platform combines a potent, plant-derived cytotoxin (thapsigargin) with a pro-drug delivery system that releases the drug only within the tumor.  Unlike standard cancer drugs, thapsigargin kills cells independent of their division rate, thus making it effective at killing all fast- and slow-growing cancers and cancer stem cells. GenSpera’s pro-drug platform is the subject of seven issued patents with four additional patents pending.

In early 2010, GenSpera initiated a Phase I clinical trial targeting solid tumor cancers with its lead drug, G-202, at Johns Hopkins University and the University of Wisconsin.  The Company anticipates completion of Phase I trials in Q2 2011.  Upon successful completion of its Phase I trial, GenSpera expects to initiate multiple Phase II trials for G-202 in several different types of cancer.  The company’s second drug, G-115, will directly target prostate cancer.  The Company anticipates filing an application to commence Phase I trials of G-115 in Q3 2011.

GenSpera, Inc. owns and controls all rights to G-202 and G-115 and expects a strategic partnership to maximize the value of the drugs as they progress through future clinical trials.

GenSpera is also developing a cancer imaging platform, derived from thapsigargin, the active ingredient in its therapeutic drugs, coupled with its patented tumor-targeted delivery system.

For more information, please visit the Company’s website: www.genspera.com.

Cautionary Statement Regarding Forward Looking Information:

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of GenSpera’s technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera’s periodic reports.

# # #